HCA vs JNJ
HCA: One of the largest U.S. for-profit hospital operators, managing 190 hospitals and 121 ambulatory surgery centers across 19 states and England, generating $76+ billion in annual revenue. JNJ: A diversified healthcare giant producing pharmaceuticals, medical devices, and consumer health products with a focus on innovation-driven therapeutic breakthroughs across oncology, immunology, infectious disease, and cardiovascular markets.
Side-by-side fundamentals
| Metric | HCA | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $409.01 | $259.10 | |
| Market cap as of 2026-07-10 | $89.9B | $625.8B | |
| P/E as of 2026-07-10 | 13.23 | 29.74 | HCA lower |
| PEG as of 2026-07-10 | 1.31 | 3.16 | HCA lower |
| Net margin as of 2026-07-10 | +8.9% | +21.8% | JNJ higher |
| Gross margin as of 2026-07-10 | +85.0% | +68.0% | HCA higher |
| Operating margin as of 2026-07-10 | +15.7% | +25.9% | JNJ higher |
| ROE as of 2026-07-10 | +695.7% | +26.3% | HCA higher |
| ROA as of 2026-07-10 | +11.3% | +10.7% | HCA higher |
| Debt / equity as of 2026-07-10 | 125.80 | 0.68 | JNJ lower |
| Revenue growth (YoY) as of 2026-07-10 | +6.7% | +7.9% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +7.9% | +6.2% | HCA higher |
| Dividend yield as of 2026-07-10 | +0.8% | +2.1% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 1.11 | 0.23 | |
| 1-year return as of 2026-07-09 close | +8.7% | +65.8% | JNJ higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.